Par Drugs and Chemicals Approves Q1 Unaudited Financial Results, Approves Strategic Asset Purchase and Banking Facility Access
Par Drugs and Chemicals Limited has announced the outcomes of its Board of Directors meeting held on August 8, 2026. The Board considered and approved the company's unaudited standalone financial results for the quarter ended June 30, 2026, alongside a Limited Review Report conducted by Sarupria Somani & Associates.The company’s management also utilized the meeting to approve several strategic actions, including the appointment of an external Portfolio Manager and making significant decisions regarding corporate assets and banking facilities.
Financial Performance Highlights
The unaudited standalone financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board. The complete Profit and Loss Statement in Lakhs is detailed below:| Particulars | Q Ended 30-06-2026 (Unaudited) | Q Ended 31-03-2026 (Audited) | Q Ended 30-06-2025 (Unaudited) | Year to Date (Q3 2026) | Year to Date (H1 2026) |
|---|---|---|---|---|---|
| Revenue from operations | 3,128.05 | 1,961.08 | 2,604.64 | 3,128.05 | 10,365.56 |
| Other income | 93.53 | 35.85 | 183.67 | 93.53 | 400.07 |
| Total Revenue | 3,221.58 | 1,996.93 | 2,788.31 | 3,221.58 | 10,765.63 |
| Cost of materials consumed | 1,283.50 | 884.59 | 1,116.32 | 1,283.50 | 4,267.05 |
| Changes in inventories of finished goods | 90.89 | 6.26 | 17.23 | 90.89 | 69.09 |
| Trade and work-in-progress Employee benefits expense | 168.92 | 193.54 | 141.97 | 168.92 | 612.01 |
| Finance costs | 2.14 | 4.14 | 1.63 | 2.14 | 12.73 |
| Depreciation and amortization expense | 96.42 | 92.75 | 90.35 | 96.42 | 370.33 |
| Other expenses | 946.70 | 732.50 | 973.04 | 946.70 | 3,704.26 |
| Total expenses | 2,588.57 | 1,913.78 | 2,340.54 | 2,588.57 | 9,035.47 |
| Profit/ (loss) before tax | 633.01 | 83.15 | 447.77 | 633.01 | 1,730.16 |
| Tax expense: Current tax | 161.74 | 31.39 | 114.97 | 161.74 | 452.90 |
| Profit for the period from continuing operations | 471.27 | 85.36 | 332.80 | 471.27 | 1,310.86 |
Strategic Corporate Transactions Approved by Board
The Board of Directors approved several key corporate transactions and operational appointments:- Banking Facilities: The company approved availing forward booking banking facilities from ICICI Bank. Falgun V. Savani, Chairman and Managing Director, along with Jignesh Vallabhbhai Savani, CEO & Director, were authorized to execute all necessary documents related to this arrangement.
- Portfolio Management: NEO Alternative Asset Managers Private Limited was appointed as a Portfolio Manager. The Board granted authorization to both Falgun V. Savani and Jignesh Vallabhbhai Savani to sign and execute all required agreements with the manager.
- Asset Acquisition and Sale: The Board approved the sale of an existing motor vehicle for approximately Rs 3.60 Lakh. Additionally, approval was granted for the purchase of new company vehicles:
* A Mahindra XEV 9E PACK-3 B-79 ruby velvet variant, valued at an ex-showroom price of Rs. 29.43 Lakh plus applicable charges, designated for Falgun V. Savani, Chairman and Managing Director.
Governance and Reporting Updates
The Board reviewed several governance and reporting items related to the quarter:- Financial Disclosure: The company approved the unaudited standalone financial results. It was further decided that advertisements regarding these results would be published in The Economic Times and Navgujarat Samay.
- Governance Review: The Board took note of the Corporate Governance Report for the quarter ended June 30, 2026, and reviewed the Investor grievances report status, noting zero pending or resolved complaints during the period.
- Policy Approval: After a recommendation from the Audit Committee, the Policy on Communication between Statutory Auditor and Those Charged with Governance was approved by the Board.
PAR Stock Price Movement
On Friday, shares of Par Drugs And Chemicals Limited shed value, closing down 1.75% to settle at ₹98.40. The stock saw a total traded volume of 4,769 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: